[Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)].

Yan Sun, Zhongzhen Guan, Meilin Liao, Xin Yu, Changli Wang, Jie Wang, Xiaohui Niu, Yuankai Shi, Xiuyi Zhi, Yunpeng Liu, Mengzhong Liu, Yiping Zhang, Yue Yang, Jingnan Shen, Gongyan Chen, Qinghua Zhou, Caicun Zhou, Qisen Guo, Lili Tang, Jianchun Duan, Jun Liang, Yingjian Zhang, Ying ChengPubMed 2014 · DOI

TL;DR

This paper presents a 2014 expert consensus on diagnosing and treating bone metastasis in lung cancer. It emphasizes a multidisciplinary approach, integrating systemic therapy, local treatments, pain management, and crucial psychological support to improve patient quality of life and survival.

What Problem Does This Paper Address?

Lung cancer is a leading cause of cancer-related mortality, and bone metastasis is a common and debilitating complication, significantly impacting patients' quality of life and survival. By the time of diagnosis, a substantial proportion of lung cancer patients have advanced disease, with bone metastasis being a frequent site of spread. The challenge lies in effectively managing these bone metastases and their associated skeletal-related events (SREs) such as pain, pathological fractures, spinal cord compression, and hypercalcemia. This consensus aims to provide a unified, evidence-based guideline for healthcare professionals to optimize the diagnosis and treatment of this complex condition, moving beyond solely treating the primary tumor to a holistic patient-centered approach.

Methods

The paper outlines a comprehensive diagnostic and therapeutic strategy for lung cancer with bone metastasis.

Diagnosis: * Screening: Recommends radionuclide bone scanning (ECT) or PET-CT as the primary screening tools due to their high sensitivity. * Confirmation: Utilizes X-ray, CT, and MRI for detailed assessment of bone lesions and surrounding soft tissues. * Histopathology: Emphasizes bone biopsy as the gold standard for diagnosis when imaging is inconclusive or for solitary lesions. * Biochemical Markers: Mentions bone metabolic markers (e.g., ALP, ICTP, NTX) as potential indicators but notes their current limitations for routine clinical use. * Diagnostic Criteria: Defines criteria for confirming bone metastasis based on clinical, pathological, and imaging findings. * Diagnostic Flowchart: Provides a visual guide for the diagnostic process.

Treatment: The treatment approach is multidisciplinary (MDT) and individualized, focusing on improving quality of life, prolonging survival, and managing symptoms. Key components include:

  • Systemic Therapy: Chemotherapy and targeted therapy for the primary lung cancer.
  • Local Therapy: Radiotherapy (external beam and radionuclide) and surgery for symptomatic or high-risk bone lesions.
  • Pharmacological Management: Bisphosphonates to prevent and delay SREs, and analgesics for pain management following WHO analgesic ladder principles.
  • Psychological Support: Crucial for addressing anxiety, depression, and other emotional distress associated with cancer and bone metastasis.

Datasets

Not discussed in the paper. This document is an expert consensus guideline, not a research study reporting on specific datasets.

Key Insights and Ideas

  • Holistic Patient Care: The consensus strongly advocates for a shift from solely treating the primary cancer to a comprehensive, patient-centered approach that includes psychological support as a fundamental component of care.
  • Multidisciplinary Team (MDT) is Crucial: Effective management requires collaboration between oncologists, orthopedic surgeons, radiologists, nuclear medicine specialists, and psychologists.
  • Proactive Management of SREs: The guideline emphasizes the importance of preventing and managing skeletal-related events (SREs) to maintain patient quality of life and survival.
  • Bisphosphonates as Foundational Therapy: Bisphosphonates are recommended as a standard of care for all patients with confirmed bone metastasis, not just those with symptoms, to reduce SRE risk.
  • Psychological Distress is Prevalent and Impactful: Lung cancer patients, in particular, experience high rates of anxiety and depression, which can exacerbate pain and negatively impact treatment adherence and outcomes. Addressing these issues is as vital as managing physical symptoms.
  • Individualized Treatment: The consensus stresses that treatment plans must be tailored to the patient's overall condition, tumor characteristics, and specific bone lesion.

Key Results

  • Incidence: Bone metastasis occurs in 30-40% of lung cancer patients, with up to 50% found incidentally at autopsy.
  • Survival: Median survival for lung cancer patients with bone metastasis is approximately 6-10 months, with a 1-year survival rate of only 40-50% after treatment.
  • SREs: 46% of lung cancer patients with bone metastasis experience SREs, which can halve survival time.
  • Pain Management: Pain is the most common symptom, affecting about 50% of patients with bone metastasis.
  • Treatment Efficacy: The consensus outlines specific indications and regimens for chemotherapy, targeted therapy, radiotherapy, surgery, and bisphosphonate therapy, aiming to improve symptom control and patient outcomes.

Limitations and Future Work

  • Limitations: The consensus is based on expert opinion and existing literature up to 2014. While it integrates various treatment modalities, the rapid evolution of targeted therapies and immunotherapies means some recommendations may need updating with newer evidence. The paper acknowledges the cost of PET-CT and the need for careful patient selection. The efficacy of certain interventions, like bone biopsies, is discussed in terms of necessity based on diagnostic clarity.
  • Future Work: The paper implicitly calls for ongoing research to refine treatment strategies, particularly in the areas of systemic therapy, optimizing the use of bisphosphonates, and further understanding the role of psychological interventions. The development of new targeted therapies and immunotherapies for lung cancer will undoubtedly influence the management of bone metastasis. The emphasis on MDT and individualized care suggests a future direction towards more integrated and personalized treatment pathways.

Summary updated

BibTeX
@inproceedings{sun2014expert,
  author = {Yan Sun and Zhongzhen Guan and Meilin Liao and Xin Yu and Changli Wang and Jie Wang and Xiaohui Niu and Yuankai Shi and Xiuyi Zhi and Yunpeng Liu and Mengzhong Liu and Yiping Zhang and Yue Yang and Jingnan Shen and Gongyan Chen and Qinghua Zhou and Caicun Zhou and Qisen Guo and Lili Tang and Jianchun Duan and Jun Liang and Yingjian Zhang and Ying Cheng},
  title = {{[Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)].}},
  booktitle = {PubMed},
  year = {2014},
  doi = {10.3779/j.issn.1009-3419.2014.02.01},
}
Figure